EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity

[Image: see text] Inhibitors of the protein methyltransferase Enhancer of Zeste Homolog 2 (EZH2) may have significant therapeutic potential for the treatment of B cell lymphomas and other cancer indications. The ability of the scientific community to explore fully the spectrum of EZH2-associated pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Campbell, John E., Kuntz, Kevin W., Knutson, Sarah K., Warholic, Natalie M., Keilhack, Heike, Wigle, Tim J., Raimondi, Alejandra, Klaus, Christine R., Rioux, Nathalie, Yokoi, Akira, Kawano, Satoshi, Minoshima, Yukinori, Choi, Hyeong-Wook, Porter Scott, Margaret, Waters, Nigel J., Smith, Jesse J., Chesworth, Richard, Moyer, Mikel P., Copeland, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2015
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4434464/
https://www.ncbi.nlm.nih.gov/pubmed/26005520
http://dx.doi.org/10.1021/acsmedchemlett.5b00037

Ejemplares similares

Ejemplares similares